Quality of Life and Symptom Burden
Outcomes achieved using a digital service model for COPD
Despite their progressive condition, service users returned reassuringly stable serial quality of life scores.
Service users also returned broadly stable symptom burden scores.
Let's look at what that means when considering how Lenus can transform the traditional COPD pathway.
Evidence stats
How the Lenus Service has demonstrated stable quality of life and symptom burden
-
0.46
EQ-5D score increase from initial 26-week window
-
0.35
CAT score decrease from initial 26-week window
Chart supplements
More information on the data visualised
| n | Variable with participant completion of EQ-5D entries and time period. max 83 (at baseline) |
|---|---|
| Inclusion Criteria | RECEIVER cohort criteria |
| Score Criteria |
EQ-5D Visual analogue scale score. Service users self-access their health on a vertical visual scale ranging from 0, "worst imaginable health", to 100, "best imaginable health". |
- EQ-VAS: The EQ-5D5L Visual analogue scale was used to record self-rated health.
- Users had the opportunity to complete an EQ-VAS entry once every 28 days.
- The mean score reported over each 26-week time window is shown.
| n | Variable with participant completion of CAT entries and time period. max 83 (at baseline) |
|---|---|
| Inclusion Criteria | RECEIVER cohort criteria |
| Score Criteria |
COPD assessment test (CAT) score. Service users self-assess the severity of their COPD symptoms across eight different symptom areas using a scale ranging from 0 to 5, with 0 representing the lowest level of symptom burden and 5 representing the highest. The total CAT score combines the score for each question. |
- CAT: The COPD Assessment Test was used to record self-rated symptom burden.
- Users had the opportunity to complete a CAT entry once daily.
- The mean score reported over each 26-week time window is shown.
Study details
ClinicalTrials.gov Identifier: NCT04240353
The feasibility and service adoption observational cohort RECEIVER trial was commenced in September 2019 by NHS Greater Glasgow and Clyde to evaluate the implementation and efficacy of the Lenus COPD Service with high-risk COPD participants matched 1:5 to a control cohort using de-identified contemporary routine clinical data. The protocol is published here with the full results available here.
| Control | RECEIVER | |||
|---|---|---|---|---|
| Inclusion Criteria |
Selected from the NHS Greater Glasgow and Clyde Safe Haven COPD dataset. Control cohort identification was conducted by iteratively identifying the individuals in the cohort who met the matching criteria for each RECEIVER participant. Duplicate control patients or individuals subsequently onboarded to Lenus COPD were excluded and then the optimal 5 matches for each RECEIVER participant were determined based on closest matches by age. The matching criteria were that matched individuals must: be alive at the onboarding date of the RECEIVER participant, be the same sex as the RECEIVER participant, and have had a COPD or respiratory related admission in the 7 days prior to the RECEIVER participant's onboarding date. |
At least one severe COPD exacerbation in the year prior to onboarding to Lenus COPD and/or chronic hypercapnic respiratory failure/sleep disordered breathing requiring NIV/CPAP treatment. | ||
| 1st Participant Index Date | 3rd September 2019 | |||
| Censor Date | 31st August 2021 | |||
| Total Patients | 415 | 83 | ||
NICE advice
Medtech Innovation Briefing
The National Institute of Health and Care Excellence (NICE) has developed a medtech innovation briefing (MIB) on Lenus COPD Support Service for remotely managing chronic obstructive pulmonary disease available here.
Get in touch
Got a service in mind for Lenus? Talk to us today.